Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Five-Year Follow-up of the Phase I/II Discontinuation Trial of Imatinib after Pioglitazone (EDI-PIO) in Chronic Myeloid Leukemia Patients in Deep Molecular Response

Katia B Pagnano, Ana Beatriz Pascoal Lopes, Eliana C M Cristina Martins Miranda, Marcia Delamain, Gislaine B O Duarte, Samuel de Souza Medina, Fernando Vieira Pericole, Guilherme Brasil Duffles Amarante, Bruno K Duarte, Graziele Pavan, Isabella Macedo Toni, Erich V De Paula, Carmino Antonio Souza

Blood (2022) 140 (Supplement 1): 9645–9646.

https://doi.org/10.1182/blood-2022-164598

Published: 2022

Journal Articles

The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2 nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy

Blood (2022) 140 (Supplement 1): 6774–6775.

https://doi.org/10.1182/blood-2022-168228

Published: 2022

Journal Articles

Serological Response after Two Doses of Sars-Cov-2 Vaccines in CML Patients - a Prospective Study of a Brazilian Center

Ana Carolina Mourão Toreli, Leonardo Fechio, Adriana Silva Santos Duarte, Audrey Basso, Gislaine B O Duarte, Samuel de Souza Medina, Guilherme Brasil Duffles Amarante, Fernando Vieira Pericole, Bruno Deltreggia Benites, Roberto Zulli, Carmino Antonio Souza, Marcelo Addas Carvalho, Katia B Pagnano

Blood (2022) 140 (Supplement 1): 12208–12209.

https://doi.org/10.1182/blood-2022-168108

Published: 2022

Journal Articles

Somatic Mutations Are Frequently Detected in CML Patients before Treatment-Free Remission (TFR) Attempt with Tyrosine Kinase Inhibitor (TKI) Discontinuation but with Uncertain Predictive Value for Tfr Failure

Blood (2022) 140 (Supplement 1): 6782–6783.

https://doi.org/10.1182/blood-2022-167927

Published: 2022

Journal Articles

Adult T-Cell Leukemia/Lymphoma: A Cohort of 41 Cases Recorded in the Brazilian T-Cell Project

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-142818

Published: 2020

Journal Articles

Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials

Katia B Pagnano, MD PhD, Fernanda S Seguro, MD, Eliana C Miranda, PhD, Ana Beatriz Pascoal Lopes, Andre Abdo, MD, Marcia Torresan Delamain, MD, Thales Pereira, MD, Gislaine Borba Duarte, MD, Fernanda Maria Santos, Jessica CN Vianna, Matheus Sebastian Da Silva, Luciana Nardinelli, M.Sc, Valquiria Povoa, Graziele Pavan, Bruna R Vergilio, Vanderson Rocha, MD PhD, Carmino Antonio Souza, MD PhD, Erich V De Paula, MD PhD, Israel Bendit, MD PhD

Blood (2019) 134 (Supplement_1): 1655.

https://doi.org/10.1182/blood-2019-125368

Published: 2019

Journal Articles

Pioglitazone Did Not Affect PPAR-Γ , STAT5 , HIF2α and CITED2 Gene Expression in Chronic Myeloid Leukemia Patients with Deep Molecular Response

Ana Beatriz Pascoal Lopes, Eliana C Miranda, PhD, Valquíria Mariane Oliveira Póvoa, Bruna Rocha Vergílio, Graziele Cristina Pavan Furlin, Marcia Torresan Delamain, MD, Gislaine Borba Duarte, MD, Carmino Antonio Souza, MD PhD, Erich V De Paula, MD PhD, Katia B Pagnano, MD PhD

Blood (2019) 134 (Supplement_1): 1637.

https://doi.org/10.1182/blood-2019-128265

Published: 2019

Journal Articles

Impact of Comorbidities on Survival of Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Fernanda F Engelbrecht, Eliana C Miranda, PhD, Marcia Torresan Delamain, MD, Gislaine Borba Duarte, MD, Carmino Antonio Souza, MD PhD, Erich V De Paula, MD PhD, Katia B Pagnano, MD PhD

Blood (2019) 134 (Supplement_1): 2938.

https://doi.org/10.1182/blood-2019-129388

Published: 2019

Journal Articles

Financial Impact of Imatinib Discontinuation in Brazil - a Pharmoeconomic Study

Renato Torrescasana Centrone, Isabel Bonafe, Eliana C Miranda, PhD, Fernanda S Seguro, MD, Gustavo HR Magalhaes, MD MSc, Nelma D Clementino, MD, Arthur Moellmann-Coelho, MD, Ingrid Luise, MD, Monika Conchon, MD, Natália N Gonçalves, MD, Jaisson Bortolini, MD, Laura Maria Fogliatto, MD PhD, Carmino Antonio Souza, MD PhD, Katia B Pagnano, MD PhD, Israel Bendit, MD PhD

Blood (2019) 134 (Supplement_1): 5844.

https://doi.org/10.1182/blood-2019-127530

Published: 2019

Journal Articles

A Prospective Study Comparing 99m tc-Sestamibi SPECT/CT with 18 f-FDG PET/CT in Multiple Myeloma Staging: A Potential Resource-Constraint Image Alternative for MM Bone Evaluation

Camila Mosci, MD, Fernando Vieira Pericole, MD PhD, Allan de Oliveira Santos, MD, Mariana Cunha Lima, Elba Cristina Camargo Etchebehere, Barbara Juarez Amorim, Gislaine Borba Duarte, MD, Marcia Torresan Delamain, MD, Carmino Antonio Souza, MD PhD, Irene Lorand-Metze, MD PhD, Celso Dario Ramos, MD PhD

Blood (2018) 132 (Supplement 1): 3543.

https://doi.org/10.1182/blood-2018-99-118228

Published: 2018

NARROW

Five-Year Follow-up of the Phase I/II Discontinuation Trial of Imatinib after Pioglitazone (EDI-PIO) in Chronic Myeloid Leukemia Patients in Deep Molecular Response

The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2 nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy

Serological Response after Two Doses of Sars-Cov-2 Vaccines in CML Patients - a Prospective Study of a Brazilian Center

Somatic Mutations Are Frequently Detected in CML Patients before Treatment-Free Remission (TFR) Attempt with Tyrosine Kinase Inhibitor (TKI) Discontinuation but with Uncertain Predictive Value for Tfr Failure

Adult T-Cell Leukemia/Lymphoma: A Cohort of 41 Cases Recorded in the Brazilian T-Cell Project

Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials

Pioglitazone Did Not Affect PPAR-Γ , STAT5 , HIF2α and CITED2 Gene Expression in Chronic Myeloid Leukemia Patients with Deep Molecular Response

Impact of Comorbidities on Survival of Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Financial Impact of Imatinib Discontinuation in Brazil - a Pharmoeconomic Study

A Prospective Study Comparing 99m tc-Sestamibi SPECT/CT with 18 f-FDG PET/CT in Multiple Myeloma Staging: A Potential Resource-Constraint Image Alternative for MM Bone Evaluation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only